PL3013350T3 - Zastosowanie cząsteczek hamujących semaforynę-4d w kombinacji z terapią modulującą odporność w celu hamowania wzrostu i przerzutów guza - Google Patents

Zastosowanie cząsteczek hamujących semaforynę-4d w kombinacji z terapią modulującą odporność w celu hamowania wzrostu i przerzutów guza

Info

Publication number
PL3013350T3
PL3013350T3 PL14818498T PL14818498T PL3013350T3 PL 3013350 T3 PL3013350 T3 PL 3013350T3 PL 14818498 T PL14818498 T PL 14818498T PL 14818498 T PL14818498 T PL 14818498T PL 3013350 T3 PL3013350 T3 PL 3013350T3
Authority
PL
Poland
Prior art keywords
semaphorin
metastases
combination
tumor growth
inhibit tumor
Prior art date
Application number
PL14818498T
Other languages
English (en)
Polish (pl)
Inventor
Elizabeth E. Evans
Ernest S. Smith
Maurice Zauderer
Original Assignee
Vaccinex, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex, Inc. filed Critical Vaccinex, Inc.
Publication of PL3013350T3 publication Critical patent/PL3013350T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL14818498T 2013-06-25 2014-06-20 Zastosowanie cząsteczek hamujących semaforynę-4d w kombinacji z terapią modulującą odporność w celu hamowania wzrostu i przerzutów guza PL3013350T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361839170P 2013-06-25 2013-06-25
US201361874241P 2013-09-05 2013-09-05
US201361884771P 2013-09-30 2013-09-30
US201361907845P 2013-11-22 2013-11-22
PCT/US2014/043466 WO2014209802A1 (en) 2013-06-25 2014-06-20 Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
EP14818498.9A EP3013350B1 (en) 2013-06-25 2014-06-20 Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases

Publications (1)

Publication Number Publication Date
PL3013350T3 true PL3013350T3 (pl) 2020-06-15

Family

ID=52142579

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14818498T PL3013350T3 (pl) 2013-06-25 2014-06-20 Zastosowanie cząsteczek hamujących semaforynę-4d w kombinacji z terapią modulującą odporność w celu hamowania wzrostu i przerzutów guza

Country Status (18)

Country Link
US (5) US9243068B2 (ko)
EP (2) EP3013350B1 (ko)
JP (3) JP6611709B2 (ko)
KR (2) KR20210104166A (ko)
CN (1) CN105492016A (ko)
AU (2) AU2014302812B2 (ko)
BR (1) BR112015032690B1 (ko)
CA (2) CA2916245C (ko)
DK (1) DK3013350T3 (ko)
EA (1) EA036591B1 (ko)
ES (1) ES2782834T3 (ko)
IL (1) IL243301B (ko)
MX (1) MX2015017485A (ko)
NZ (1) NZ631015A (ko)
PL (1) PL3013350T3 (ko)
PT (1) PT3013350T (ko)
SG (2) SG10201902380SA (ko)
WO (1) WO2014209802A1 (ko)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010245668B2 (en) 2009-05-08 2016-07-14 Vaccinex, Inc. Anti-CD100 antibodies and methods for using the same
AU2012322721B2 (en) 2011-10-11 2016-05-05 Vaccinex, Inc. Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
DK3013350T3 (da) 2013-06-25 2020-04-14 Vaccinex Inc Anvendelse af semaphorin-4D-hæmmende molekyler i kombination med en immunmodulerende terapi for at hæmme tumorvækst og metastaser
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
WO2015167616A1 (en) * 2014-05-02 2015-11-05 Nitor Therapeutics Guanosine as an immunepotentiator mediated through toll receptors
US10973843B2 (en) 2016-01-27 2021-04-13 University Of Maryland, Baltimore Method for monitoring cancer and for regulation of semaphorin 4D to improve cancer immunotherapy regimens
EP3213768A1 (en) 2016-03-01 2017-09-06 LODOCO CLINICAL Kft Combination of low dose immune checkpoint blockade with high dose il-2 for treating metastatic cancer
KR102403660B1 (ko) * 2016-04-18 2022-05-30 파론 파머수티컬스 오와이 CLEVER-1, TNF-α 및 HLA-DR 결합제를 사용하는 면역 활성화의 진단
KR102558637B1 (ko) 2016-04-22 2023-07-24 백시넥스 인코포레이티드 폭스바이러스 세포외 피막형 비리온 상에서의 내재막 단백질 디스플레이
EP3473262A4 (en) * 2016-06-16 2020-03-18 The University Of Tokyo PLEXIN BINDING REGULATOR
IL264343B2 (en) 2016-08-02 2024-05-01 Vaccinex Inc Improved methods for generating polynucleotide libraries in cowpox/eukaryotic cells
USD889258S1 (en) * 2016-08-04 2020-07-07 Carolin McKie Beverage container identification marker kit
CN110300598A (zh) * 2016-09-16 2019-10-01 布里格姆妇女医院有限公司 Klrg1消耗治疗
KR102661905B1 (ko) * 2016-10-12 2024-04-29 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Tusc2 면역요법을 위한 방법 및 조성물
AU2018219226A1 (en) 2017-02-07 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
DK3600419T5 (en) * 2017-03-20 2024-05-27 Vaccinex Inc Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
EP3612210A4 (en) 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System IMMUNE CELLS EXPRESSING MODIFIED ANTIGEN RECEPTORS
US11427634B2 (en) 2017-05-05 2022-08-30 Vaccinex, Inc. Human anti-semaphorin 4D antibody
CA3089319A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
EP3693380A1 (en) * 2019-02-11 2020-08-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Dual inhibition of plexin-b1 and plexin-b2
AU2020244862B2 (en) * 2019-03-28 2023-01-05 Merck Kgaa Semaphorin-4D antagonists for use in cancer therapy
EP3986446A1 (en) 2019-06-21 2022-04-27 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy
CA3152371A1 (en) 2019-08-01 2021-02-04 Vaccinex, Inc. Combined inhibition of semaphorin-4d and tgf.beta. and compositions therefor
CN111158663B (zh) * 2019-12-26 2021-07-02 深圳逻辑汇科技有限公司 用于处理程序代码中的变量的引用的方法和系统
WO2021262564A1 (en) * 2020-06-25 2021-12-30 Vaccinex, Inc. Use of semaphorin-4d binding molecules for the treatment of rett syndrome
US20230390345A1 (en) * 2020-08-21 2023-12-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Combination therapy comprising her-2-dc1 vaccine, a probiotic, and semaphorin
CN112233123B (zh) * 2020-09-21 2024-05-14 广州金域医学检验中心有限公司 病理图片中肿瘤间质分类方法、装置、计算机设备及存储介质
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2023012314A1 (en) * 2021-08-05 2023-02-09 Lifearc Anti-plexin-b1 antibodies
CN117802242A (zh) * 2024-01-22 2024-04-02 深圳慕光生物科技有限公司 一种利用sema4d基因预测肿瘤免疫逃避风险的方法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5070192A (en) 1988-03-23 1991-12-03 The Johns Hopkins University Cloned human topoisomerase i: cdna expression, and use for autoantibody detection
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5639856A (en) 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
NZ500078A (en) 1997-04-07 2001-10-26 Genentech Inc Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
WO1998046769A1 (en) 1997-04-11 1998-10-22 Dendreon Corporation Composition and method for inducing an immune response against tumour-related antigens
EP0892047A3 (de) 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Humanes und murines Semaphorin L
EP1137769B1 (en) 1998-11-10 2008-09-03 University Of Rochester Methods for the generation of dna libraries
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
JP3787473B2 (ja) 1999-11-30 2006-06-21 独立行政法人科学技術振興機構 セマフォリン受容体
US6635742B1 (en) 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
WO2002102972A2 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1365018A1 (en) 2002-05-23 2003-11-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) CD100 semaphorin in myelination
BR0311471A (pt) 2002-05-30 2007-04-27 Macrogenics Inc anticorpo anti-cd16a, e, métodos de redução de uma resposta imune deletéria em um mamìfero e de tratamento de uma resposta imune deletéria em um mamìfero
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
KR20120104408A (ko) 2003-05-30 2012-09-20 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
JP5042631B2 (ja) 2003-12-04 2012-10-03 バクシネックス インコーポレーティッド アポトーシス腫瘍細胞上に露出した細胞内抗原をターゲッティングすることによって腫瘍細胞を死滅させる方法
AU2004298483A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
RS51326B (sr) * 2004-08-05 2010-12-31 Genentech Inc. Humanizovani anti-cmet antagonisti
US20060147449A1 (en) 2004-11-15 2006-07-06 Brass Lawrence F Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses
JP2008535856A (ja) 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 癌の診断、検出および治療におけるｓｅｍａ４ｄ
AU2006236439B2 (en) 2005-04-15 2012-05-03 Macrogenics, Inc. Covalent diabodies and uses thereof
JP2007308465A (ja) 2006-05-15 2007-11-29 Boehringer Ingelheim Internatl Gmbh 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
US7919594B2 (en) 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
US9603922B2 (en) 2007-02-21 2017-03-28 Vaccinex, Inc. Modulation of NKT cell activity with antigen-loaded CD1d molecules
CN101932333A (zh) 2007-12-26 2010-12-29 瓦西尼斯公司 抗c35抗体联合疗法和方法
US20090181035A1 (en) * 2008-01-10 2009-07-16 Genentech, Inc. Plexind1 agonists and their use
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
AU2010245668B2 (en) 2009-05-08 2016-07-14 Vaccinex, Inc. Anti-CD100 antibodies and methods for using the same
JP5797190B2 (ja) * 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス， インコーポレイテッド ワクチン免疫療法
NZ605260A (en) 2010-06-14 2013-12-20 Joseph King Allan Anti-vegf antibodies and uses thereof
JP6097690B2 (ja) 2010-09-02 2017-03-15 ヴァクシネックス， インコーポレイテッド 抗ｃｘｃｌ１３抗体およびそれを用いる方法
WO2012157237A1 (ja) 2011-05-13 2012-11-22 国立大学法人東京医科歯科大学 骨形成促進剤
JP2015501295A (ja) 2011-10-06 2015-01-15 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 疾患を治療するのに有用な抗ヒトｓｅｍａ４Ａ抗体
AU2012322721B2 (en) 2011-10-11 2016-05-05 Vaccinex, Inc. Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
CA2762446C (en) * 2011-12-06 2021-02-23 Vaccinex, Inc. Use of the combination of semaphorin-4d inhibitory molecules and vegf inhibitory molecules to inhibit angiogenesis
IN2014DN08199A (ko) 2012-03-02 2015-05-01 Vaccinex Inc
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
EP2951204B1 (en) 2013-01-31 2019-05-22 Vaccinex, Inc. Methods for increasing immunoglobulin a levels
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
DK3013350T3 (da) * 2013-06-25 2020-04-14 Vaccinex Inc Anvendelse af semaphorin-4D-hæmmende molekyler i kombination med en immunmodulerende terapi for at hæmme tumorvækst og metastaser
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
KR102558637B1 (ko) 2016-04-22 2023-07-24 백시넥스 인코포레이티드 폭스바이러스 세포외 피막형 비리온 상에서의 내재막 단백질 디스플레이
IL264343B2 (en) 2016-08-02 2024-05-01 Vaccinex Inc Improved methods for generating polynucleotide libraries in cowpox/eukaryotic cells
JP2020510845A (ja) 2017-02-22 2020-04-09 バクシネックス インコーポレーティッド 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法

Also Published As

Publication number Publication date
JP7021153B2 (ja) 2022-02-16
SG11201510505VA (en) 2016-01-28
NZ755091A (en) 2020-12-18
AU2019208274A1 (en) 2019-08-15
EA201690080A1 (ru) 2016-06-30
US20150044219A1 (en) 2015-02-12
EP3013350A4 (en) 2017-02-22
AU2014302812A1 (en) 2016-01-21
BR112015032690B1 (pt) 2020-03-10
JP2022058876A (ja) 2022-04-12
US9828435B2 (en) 2017-11-28
EA036591B1 (ru) 2020-11-26
KR20160024391A (ko) 2016-03-04
JP6611709B2 (ja) 2019-11-27
BR112015032690A8 (pt) 2018-01-23
NZ631015A (en) 2019-08-30
IL243301A0 (en) 2016-03-31
US20190248914A1 (en) 2019-08-15
JP2016528195A (ja) 2016-09-15
CA3098741A1 (en) 2014-12-31
BR112015032690A2 (pt) 2017-07-25
US12070500B2 (en) 2024-08-27
CA2916245C (en) 2023-01-24
EP3013350A1 (en) 2016-05-04
CN105492016A (zh) 2016-04-13
US11078295B2 (en) 2021-08-03
AU2014302812B2 (en) 2019-07-11
SG10201902380SA (en) 2019-04-29
EP3656392A1 (en) 2020-05-27
US9243068B2 (en) 2016-01-26
IL243301B (en) 2020-06-30
KR20210104166A (ko) 2021-08-24
US10526414B2 (en) 2020-01-07
PT3013350T (pt) 2020-04-08
ES2782834T3 (es) 2020-09-16
JP2019213530A (ja) 2019-12-19
US20210324103A1 (en) 2021-10-21
JP7356531B2 (ja) 2023-10-04
CA2916245A1 (en) 2014-12-31
US20170335008A1 (en) 2017-11-23
MX2015017485A (es) 2016-03-31
EP3013350B1 (en) 2020-01-08
DK3013350T3 (da) 2020-04-14
WO2014209802A1 (en) 2014-12-31
US20160115240A1 (en) 2016-04-28
KR102291971B1 (ko) 2021-08-19

Similar Documents

Publication Publication Date Title
IL243301B (en) Use of inhibitory molecules of the semphorin d4 type - in combination with immunomodulation therapy to inhibit tumor growth and metastases
IL290295A (en) A combination of antibodies against lag-3 and antibodies against pd-1 for the treatment of tumors
HK1216991A1 (zh) 癌疫苗及使用其的治療方法
EP2943565A4 (en) COMPOSITIONS AND METHODS FOR ADMINISTRATION OF IMMUNE CELLS FOR TREATING TUMOR CELLS THAT ARE NOT RESTRICTED OR UNREQUIRED AND A TUMOR RECIPIENT
HK1221178A1 (zh) 卡博替尼劑型及其在癌症治療中的使用
EP2836270A4 (en) SYSTEMS AND METHODS RELATED TO THE TREATMENT OF BACK PAIN
HK1225962A1 (zh) 使用溶瘤腺病毒的腦癌治療
ZA201602380B (en) Cancer treatment with combination of plinabulin and taxane
GB201406473D0 (en) The use of phytocannabinoids in the treatment of ovarian and skin carcinoma
GB2515865B (en) Use of galactooligosaccharides in therapy
HK1221390A1 (zh) 關於造影劑施用的方法和工具
EP2958591A4 (en) METHODS AND COMPOSITIONS RELATED TO THE TREATMENT OF CANCER
EP2950818A4 (en) TUMORIN VEGETABLES AND METHOD FOR USE THEREOF
GB201322958D0 (en) Uses of oligouronates in cancer treatment
TH1501007670A (th) การใช้โมเลกุลที่ยับยั้งเซมาโฟริน-4D(semaphorin-4D) ในการรวมกับสารรักษาโรคที่ปรับเปลี่ยนภูมิคุ้มกันในการยับยั้งการโตของเนื้องอก และการแพร่กระจายของเนื้อร้าย(metastases)
SG10201802995SA (en) Cancer treatment with combination of plinabulin and taxane